| おすすめ分野 | がん研究 |
|---|---|
| 開催日 | 2025年10月02日～2025年10月02日 |
| 会場 | オンライン |
| 開催内容 | • Role of Protein Arginine Methyltransferases (PRMTs) in breast cancer: emerging therapeutic targets • Insights into a novel predictive biomarker that could overcome resistance to endocrine therapy in breast cancer • Application of advanced proteomic technologies to uncover protein interactomes in cancer research |
| 開催エリア | オンライン |
| 開催形式 | ウェビナー |
| 主催者名 | CHEMEXPRESS JAPAN |
| 申し込み方法 | 詳細URLをご確認ください。 |
| 詳細URL | https://www.medchemexpress.com/webinar-Muriel.html |
CHEMEXPRESS JAPAN
Role of Protein Arginine Methyl Transferases in Steroid Receptors Signaling in Breast Cancer: From Basic Science to Clinical Perspectives
日時: 2025年10月2日（木）22時開始（日本時間）
費用：無料
言語:英語
開催形式：ウェビナー
In this Webinar, You Will Learn:
Breast cancer is the most common and deadliest cancer in women worldwide. While early-stage is curable in 75% of patients, advanced metastatic breast cancer remains largely incurable with current therapies. Breast cancer is an heterogenous disease categorized into three main subtypes based on the expression of key markers orientating specific treatment strategies for each subtype. The complexity of breast carcinogenesis is often associated with epigenetic modification regulating signaling pathways involved in breast tumor initiation, progression and relapse to treatments. In this context, my team is interested in the role of Protein Arginine Methyl Transferases (PRMTs) in the signaling of steroid receptors in different subtypes of breast cancer.
We have shown that PRMT1, by methylating the estrogen receptor ERα, regulates the estrogen non genomic signaling, participating in the resistance to endocrine therapy. More recently, we found that in triple negative breast cancer, PRMT5 forms a complex with the glucocorticoid receptor (GR), regulating the transcription of genes involved in motility, thereby promoting glucocorticoid-induced cell migration. On the contrary, in ERα+ tumors, although cytoplasmic PRMT5 possesses oncogenic properties, nuclear PRMT5 is a predictive biomarker of response to anti-estrogens. Using innovative proteomic approaches, we are currently investigating how PRMT5 nuclear shuttling is regulated to favor its nuclear localization and maximize the response to anti-estrogens therapy.
サイサチ受託サービスカタログ掲載の
がん研究関連受託実験サービスの比較検討はいかがでしょうか
